According to GII’s Ultrasonic Scalpel Global Market Report 2026, the global market reached $2.92 billion in 2025, is forecast at $3.12 billion in 2026, and may reach $3.94 billion by 2030 (CAGR ~6%).
Market restructuring favors domestic brands
While J&J, Medtronic, and Olympus retain strong positions, Chinese manufacturers including BBT Medical have entered the global competitive tier. Competition now spans performance, thermal safety, durability, training, and service—not hardware alone.
Since April 2026, multiple provinces including Guangdong, Jiangxi, Jiangsu, and Shandong have advanced ultrasonic tip VBP listing and renewal, further enabling cost-effective domestic adoption.
Clinical demand and technology upgrade
Ultrasonic devices are core to thyroid, laparoscopic, and gynecologic oncology surgery worldwide. Product lines are evolving from single-frequency ultrasound to dual-energy and multi-energy fusion platforms.
BBT’s RF-ultrasonic series holds Class III registrations, supports 47 kHz and 55 kHz workflows, and seals vessels up to 7 mm—matching international benchmarks while winning share through VBP pricing.
From follow to parallel run
Policy support for import substitution, mastered transducer and energy-control technology, and rising demand from primary hospitals create a historic window for Chinese ultrasonic brands to expand domestically and globally.
BBT Medical will continue investing in minimally invasive innovation alongside domestic peers to strengthen China’s role in the global ultrasonic scalpel market.
